Zacks Research Issues Positive Outlook for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Zacks Research increased their Q4 2026 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued to investors on Tuesday, January 20th. Zacks Research analyst Team now forecasts that the biotechnology company will earn $0.23 per share for the quarter, up from their prior estimate of $0.16. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q3 2027 earnings at ($0.01) EPS.

A number of other analysts have also weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company increased their price target on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research report on Monday, January 5th. Citigroup raised Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Citizens Jmp upgraded Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 target price on the stock in a research note on Monday, January 5th. Finally, Craig Hallum upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $5.74.

Ironwood Pharmaceuticals Trading Up 1.5%

IRWD opened at $5.39 on Wednesday. Ironwood Pharmaceuticals has a 12-month low of $0.53 and a 12-month high of $5.78. The firm has a 50 day moving average of $3.73 and a two-hundred day moving average of $2.15. The firm has a market capitalization of $876.85 million, a PE ratio of 33.69 and a beta of 0.18.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Monday, November 10th. The biotechnology company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.15. Ironwood Pharmaceuticals had a negative return on equity of 15.17% and a net margin of 8.70%.The firm had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Large investors have recently bought and sold shares of the business. AQR Capital Management LLC increased its position in shares of Ironwood Pharmaceuticals by 535.8% in the first quarter. AQR Capital Management LLC now owns 2,523,875 shares of the biotechnology company’s stock valued at $3,710,000 after buying an additional 2,126,889 shares in the last quarter. Millennium Management LLC lifted its holdings in Ironwood Pharmaceuticals by 186.6% in the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after purchasing an additional 4,140,439 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Ironwood Pharmaceuticals during the 1st quarter worth $57,000. Goldman Sachs Group Inc. boosted its stake in Ironwood Pharmaceuticals by 72.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,575,416 shares of the biotechnology company’s stock worth $2,316,000 after purchasing an additional 660,144 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Ironwood Pharmaceuticals by 740.5% during the first quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock worth $5,160,000 after buying an additional 3,092,475 shares in the last quarter.

Key Ironwood Pharmaceuticals News

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Zacks sharply raised its FY2026 outlook — the firm boosted its full‑year 2026 EPS estimate from $0.39 to $0.98, and materially raised Q1, Q2 and Q3 2026 EPS forecasts (Q1 to $0.07, Q2 to $0.27, Q3 to $0.40). These upgrades imply stronger near‑term profitability expectations that can support multiple expansion and the stock’s move higher. MarketBeat IRWD
• Neutral Sentiment: Zacks maintained a “Strong‑Buy” rating on IRWD — the positive rating lends conviction to the estimate changes but is an analyst view rather than company guidance. Also, the consensus full‑year EPS shown in the report ($0.10) remains lower than Zacks’ internal FY2026 projection, indicating some divergence between Zacks and broader analyst consensus. MarketBeat IRWD
• Negative Sentiment: Zacks trimmed several 2027 quarter forecasts (e.g., Q3 2027 to ($0.01), Q4 2027 to ($0.02) and Q4 2027 earlier flagged as negative), signaling potential softening beyond 2026. Those cuts introduce risk to longer‑term growth assumptions and could pressure the stock if investors focus on sustainability of earnings. MarketBeat IRWD

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.